Growth Factor Therapies for Neurodegeneration
Introduction <table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Growth Factor Therapies for Neurodegeneration</th> </tr> <tr> <td class="label">Agent</td> <td>Type</td> </tr> <tr> <td class="label">BDNF protein</td> <td>Native protein</td> </tr> <tr> <td class="label">7,8-DHF</td> <td>BDNF mimetic</td> </tr> <tr> <td class="label">TrkB agonists</td> <td>Small molecule</td> </tr> <tr> <td class="label">AAV-BDNF</td> <td>Gene therapy</td> </tr> <tr> <td class="label">Agent</td> <td>Type</td> </tr> <tr> <td class="label">GDNF protein</td> <td>Native protein</td> </tr> <tr> <td class="label">Neurturin</td> <td>Native protein</td> </tr> <tr> <td class="label">AAV2-Neurturin</td> <td>Gene therapy</td> </tr> <tr> <td class="label">Agent</td> <td>Target</td> </tr> <tr> <td class="label">NGF (NGF)</td> <td>TrkA</td> </tr> <tr> <td class="label">IGF-1</td> <td>IGF-1R</td> </tr> <tr> <td class="label">FGF-20</td> <td>FGFR1</td> </tr> </table>
Growth Factor Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
...
Growth Factor Therapies for Neurodegeneration
Introduction <table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Growth Factor Therapies for Neurodegeneration</th> </tr> <tr> <td class="label">Agent</td> <td>Type</td> </tr> <tr> <td class="label">BDNF protein</td> <td>Native protein</td> </tr> <tr> <td class="label">7,8-DHF</td> <td>BDNF mimetic</td> </tr> <tr> <td class="label">TrkB agonists</td> <td>Small molecule</td> </tr> <tr> <td class="label">AAV-BDNF</td> <td>Gene therapy</td> </tr> <tr> <td class="label">Agent</td> <td>Type</td> </tr> <tr> <td class="label">GDNF protein</td> <td>Native protein</td> </tr> <tr> <td class="label">Neurturin</td> <td>Native protein</td> </tr> <tr> <td class="label">AAV2-Neurturin</td> <td>Gene therapy</td> </tr> <tr> <td class="label">Agent</td> <td>Target</td> </tr> <tr> <td class="label">NGF (NGF)</td> <td>TrkA</td> </tr> <tr> <td class="label">IGF-1</td> <td>IGF-1R</td> </tr> <tr> <td class="label">FGF-20</td> <td>FGFR1</td> </tr> </table>
Growth Factor Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Growth factors are proteins that regulate cell survival, proliferation, differentiation, and function. Neurotrophic growth factors are essential for neuronal survival and synaptic plasticity. Delivery of growth factors or their mimetics represents a promising therapeutic approach for neurodegenerative diseases. [@ngf]
Key Growth Factor Systems
Neurotrophins
BDNF (Brain-Derived Neurotrophic Factor)
NGF (Nerve Growth Factor)
NT-3 (Neurotrophin-3)
NT-4/5 (Neurotrophin-4/5)
Glial Cell Line-Derived Neurotrophic Factor Family
GDNF (Glial Cell Line-Derived Neurotrophic Factor)
Neurturin
Artemin
Persephin
Fibroblast Growth Factors
FGF-2 (bFGF)
FGF-20
FGF-21
Other Growth Factors
IGF-1 (Insulin-like Growth Factor-1)
EGF (Epidermal Growth Factor)
VEGF (Vascular Endothelial Growth Factor)
Molecular Mechanism
Receptor Signaling Growth factors signal through: [@gdnf]
Tyrosine kinase receptors (TrkA/B/C, Ret, FGFR)
P75NTR (pan-neurotrophin receptor)
downstream pathways :
Neuroprotective Effects
Anti-apoptotic : Activation of survival pathways
Synaptic plasticity : Enhanced spine formation, [LTP](/mechanisms/long-term-potentiation)
Neurogenesis : Support of neural stem cells
Axonal growth : Promotes regeneration
Glial support : Protects oligodendrocytes
Anti-inflammatory : Modulates [microglia](/entities/microglia)
Disease-Specific Applications
Alzheimer's Disease
Parkinson's Disease
GDNF: Dopaminergic neuron protection
Neurturin: Clinical trials
BDNF: Nigral neuron survival
Research: PMID:10400110 , PMID:10930470
Amyotrophic Lateral Sclerosis
Huntington's Disease
BDNF: Reduced in HD, therapeutic target
CNTF: Neuroprotective effects
IGF-1: Synaptic function
Research: PMID:14690788 , PMID:15694523
Stroke
NGF, BDNF: Post-stroke recovery
VEGF: Angiogenesis
FGF: Neurogenesis
Research: PMID:14744759
Clinical Candidates
BDNF and BDNF Mimetics
GDNF Family
Other Growth Factors
Clinical Considerations
Challenges
Delivery : [BBB](/entities/blood-brain-barrier) limits systemic delivery
Half-life : Short protein half-life
Side effects : Off-target effects possible
Dosing : Chronic infusion needed
Cost : High manufacturing costs
Delivery Methods
Intranasal : Bypasses BBB for some proteins
Intracerebral : Direct to brain (invasive)
Gene therapy : AAV-mediated expression
Cell therapy : Genetically engineered cells
Research Directions
BBB-penetrant small molecules
TrkB-selective agonists
Sustained release formulations
Gene therapy vectors
Cellular delivery systems
Background The study of Growth Factor Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
[BDNF Gene](/genes/bdnf)
[GDNF Gene](/genes/gdnf)
[Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling)
[Treatments for Alzheimer's Disease](/therapeutics/alzheimers-treatment)
[Treatments for Parkinson's Disease](/therapeutics/parkinsons-treatment)
[Treatments for ALS](/therapeutics/als-treatment)
[Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
[FGF20 Gene](/genes/fgf20)
[FGF20 Protein](/proteins/fgf20-protein)
External Links
[Neurotrophin Trk Receptors - IUPHAR](https://www.guidetopharmacology.org/GRAD/FamilyDisplayForward?familyId=2)
[GDNF Family - NCBI](https://www.ncbi.nlm.nih.gov/gene/2698)
[BDNF and Neurodegeneration - Nature](https://www.nature.com/subjects/brain-derived-neurotrophic-factor)
References
[Unknown, - BDNF in CNS disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/10341227/)
[Unknown, - NGF and Alzheimer's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/14653450/)
[Unknown, - GDNF in Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/10400110/)
[Unknown, - Neurturin clinical trials (n.d.)](https://pubmed.ncbi.nlm.nih.gov/10930470/)
[Unknown, - Neurotrophic factors in ALS (n.d.)](https://pubmed.ncbi.nlm.nih.gov/11592541/)
[Unknown, - BDNF in Huntington's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/14690788/)
[Unknown, - Growth factors in stroke (n.d.)](https://pubmed.ncbi.nlm.nih.gov/14744759/)
[Unknown, - Growth factor delivery challenges (n.d.)](https://pubmed.ncbi.nlm.nih.gov/15761078/)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) 🔄
[Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) 🔄
Show full description